Kezar Life Sciences, Inc. (KZR)
NASDAQ: KZR · Real-Time Price · USD
6.85
-0.33 (-4.60%)
At close: Mar 13, 2026, 4:00 PM EDT
7.08
+0.23 (3.36%)
After-hours: Mar 13, 2026, 4:48 PM EDT

Kezar Life Sciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
--7---
Gross Profit
--7---
Selling, General & Admin
20.8123.3926.5420.1515.7211.97
Research & Development
44.7165.7485.751.0138.9430.98
Other Operating Expenses
-0.011.476.19---
Total Operating Expenses
65.5190.61118.4271.1654.6642.95
Operating Income
-65.51-90.61-111.42-71.16-54.66-42.95
Interest Income
5.388.4611.14.110.191.21
Interest Expense
-1.04-1.59-1.55-1.19-0.16-
Other Non-Operating Income (Expense)
-0.54-----
Total Non-Operating Income (Expense)
3.86.879.552.920.031.21
Pretax Income
-61.71-83.74-101.87-68.24-54.63-41.74
Net Income
-61.71-83.74-101.87-68.24-54.63-41.74
Net Income to Common
-61.71-83.74-101.87-68.24-54.63-41.74
Shares Outstanding (Basic)
777754
Shares Outstanding (Diluted)
777754
Shares Change (YoY)
0.36%0.48%7.70%27.69%19.90%130.58%
EPS (Basic)
-8.44-11.49-14.04-10.13-10.40-9.50
EPS (Diluted)
-8.44-11.49-14.04-10.13-10.40-9.50
Free Cash Flow
-56.66-74.24-83.46-60.42-42.75-37.14
Free Cash Flow Per Share
-7.75-10.18-11.50-8.97-8.10-8.44
Gross Margin
--100.00%---
Operating Margin
---1591.77%---
Profit Margin
---1455.29%---
FCF Margin
---1192.21%---
EBITDA
-64.53-89.57-110.36-70.14-53.15-41.41
EBITDA Margin
---1576.54%---
EBIT
-65.51-90.61-111.42-71.16-54.66-42.95
EBIT Margin
---1591.77%---
Updated Nov 12, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q